rivacor 7 hf-t qp - biventricular pacemaker/defibrillator
biotronik australia pty ltd - 47270 - biventricular pacemaker/defibrillator - a triple chamber rate adaptive icd, with is4 port connecting a quadripolar lv lead, home monitoring functions, max. shock of 40j and df4/is4/is-1 connector. biocompatible titanium housing is hermetically sealed and serves as a potential antipole during shock delivery or in the case of unipolar lead configuration. ellipsoid shape facilitates implanting in the pectoral muscle area. connections for bipolar pacing, sensing, unipolar connections and shock delivery are in the header. mr conditional. rivacor 7 hf-t qp belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias and cardiac resynchronization therapy with multisite ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: ?termination of spontaneous ventricular fibrillation (vf) through shock delivery ?termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerated vts, with shock delivery ?cardiac resynchronization through multisite ventricular pacing ?compensation of bradycardia through av sequential pacing. hf-t qp devices with dx functionality are only indicated for patients not requiring atrial pacing. triple-chamber icds are indicated for patients with the following risks: ?sudden cardiac death caused by ventricular arrhythmias ?congestive heart failure with ventricular asynchrony
slow-trasicor 160mg tablets
advanz pharma - oxprenolol hydrochloride - modified-release tablet - 160mg
trimacor 1000 mg weichkapsel
ibsa farmaceutici italia - eicosapentaensäure; docosahexaensäure; tocopherol-d-alpha - weichkapsel - 1000 mg - eicosapentaensäure 460 mg; docosahexaensäure 380 mg; tocopherol-d-alpha 4 mg - omega-3-triglycerides incl. other esters and acids
biotronik rivacor implantable cardioverter defibrillator
biotronik asia pacific pte. ltd. - cardiovascular - rivacor belongs to a family of implantable cardioverter-defibrillators (icds). the primary objective of the therapy is to prevent sudden cardiac death. furthermore, the device is capable of treating bradycardia arrhythmias and cardiac resynchronization therapy with multisite ventricular pacing. the implantation of an icd is a symptomatic therapy with the following objectives: termination of spontaneous ventricular fibrillation (vf) through shock delivery; termination of spontaneous ventricular tachycardia (vt) through antitachycardia pacing (atp); in case of ineffective atp or hemodynamically not tolerated vts, with shock delivery; cardiac resynchronization through multisite ventricular pacing (triple-chamber devices); compensation of bradycardia through ventricular (single-chamber devices) or av sequential pacing (dx, dual- and triple- chamber devices). vr-t dx and hf-t/hf-t qp devices types with dx functionality are only indicated for patients not requiring atrial pacing.
trasicor 40mg tablets
amdipharm plc - oxprenolol hydrochloride - oral tablet - 40mg
trasicor 20mg tablets
amdipharm plc - oxprenolol hydrochloride - oral tablet - 20mg
trasicor 80mg tablets
amdipharm plc - oxprenolol hydrochloride - oral tablet - 80mg
trasicor 80mg tablets
sigma pharmaceuticals plc - oxprenolol hydrochloride - oral tablet - 80mg
trasicor 80mg tablets
stephar (u.k.) ltd - oxprenolol hydrochloride - oral tablet - 80mg
ceftriacor 1g polvo para solucion inyectable
corval pharmaceutical s.a.c. - droguerÍa - polvo para solucion inyectable - por vial - - ceftriaxona